Stryker’s orthopedic growth has continued through the third quarter, and momentum is expected especially in shoulder care, according to an Oct. 30 earnings call.
Five key takeaways
1. Orthopedics grew 11.4% organically, and Mako robotics was an important driver, CFO Preston Wells said, as transcribed by Seeking Alpha.
2. The ASC has been a key driver for Stryker’s orthopedic growth as more shoulder cases are moving to the outpatient setting, CEO Kevin Lobo said.
3. Mako Shoulder is still in a limited release, but a full launch is expected for the second half of 2026, Mr. Lobo said.
4. Stryker’s U.S. knee business grew 8.4% organically year over year, “reflecting our market-leading position in robotic-assisted knee procedures and continued momentum from new Mako installations,” Mr. Wells said. U.S. hip business saw similar organic growth supported by the Insignia hip stem and continued adoption of Mako’s hip platform.
5. The ASC landscape has been highly beneficial to Stryker’s orthopedics, Mr. Lobo said in the earnings call.
“We love the ASC and the trend in procedures moving to the ASC because we can leverage our full portfolio, and our growth continues to be very high in the ASC,” he said. “The additional products are really — that are starting to emerge at a higher level are torn shoulder where we’re the market leader and you’re seeing more shoulders being done in the ASC [and] even some total ankles potentially moving to the ASC. So some of the higher acuity cases, I wouldn’t say revisions, but certainly, many other procedures are starting to move to ASC, where we have a very strong position. So the more that procedures move to the ASC in the orthopedic world, the better it is for Stryker because we can then leverage an even broader portfolio than we’re already leveraging, including our capital, our disposables and our inputs.”
